- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05575648
Dual Task in Duchenne Muscular Dystrophy
February 26, 2024 updated by: Büşra Kayabınar, Hacettepe University
Investigation of Dual Task Performance in Children With Duchenne Muscular Dystrophy
This study was planned to determine the effects of the dual-task performance of children with DMD with motor dysfunction and varying degrees of cognitive impairment compared to their healthy peers, to compare the dual-task performance of children with different functional levels, and to determine the relationship between parameters that may affect dual-task performance.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Children who are at least 6 years old and who can walk 10 meters independently, whose Duchenne's muscular dystrophy (DMD) diagnosis has been confirmed as a result of genetic testing, will be included in the study.
To determine dual-task performance, the 10-meter Walk Test will be performed with additional motor and cognitive tasks.
Functional level (Brooke Lower Extremity Functional Classification), ambulation level (North Star Ambulation Rating), muscular performance and functions (6 Minute Walk Test), balance (Pediatric Berg Balance Scale and four square step test), fear of falling (Fear of Falling Questionnaire), gait (Gait in DMD Assessment Scale, Gait Quality and Independence Classification Scale in DMD, and Functional Evaluation Scale for Duchenne Muscular Dystrophy-Gait Domain (FES-DMD-GD)), cognitive level (Modified Mini-Mental State Test (MMDT)), independence and activity limitation (Pediatric Functional Independence Measure (WeeFIM) and ACTIVLIM), quality of life (The Pediatric Quality of Life Inventory (PedsQL)-Neuromuscular Module Turkish version PedsQL-3.0
Neuromuscular Module) will be evaluated.
Study Type
Interventional
Enrollment (Actual)
94
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ankara, Turkey
- Hacettepe University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Study Population
Children with Duchenne Muscular Dystrophy
Description
Inclusion Criteria:
- Having been diagnosed with DMD by a pediatric neurologist,
- Must be at least 6 years old and have the ability to walk 10 meters independently,
- Being able to cooperate with the instructions given by the physiotherapist,
- Not having undergone surgery in the last 6 months and not having any injuries,
Exclusion Criteria:
- Failure to cooperate with the physiotherapist who made the evaluations,
- Have had any injury and/or surgery in the last 6 months,
- Children without consent will not be included.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Duchenne Muscular Dystrophy
Children who have been diagnosed with Duchenne Muscular Dystrophy.
|
To assess the dual task performance of children 10 meter walk test will be used.
|
|
Active Comparator: Healthy Subjects
Children who have a normal motor and cognitive development.
|
To assess the dual task performance of children 10 meter walk test will be used.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dual task performance- 10 meter walk test
Time Frame: only baseline
|
The time is measured after 10 meter walk completed
|
only baseline
|
|
Dual task performance- 10 meter walk test with cognitive task
Time Frame: only baseline
|
The time is measured after 10 meter walk with a cognitive (memory and mental) task completed
|
only baseline
|
|
Dual task performance- 10 meter walk test with motor task
Time Frame: only baseline
|
The time is measured after 10 meter walk with a motor task completed
|
only baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional level- Brooke Lower Extremity Functional Classification
Time Frame: only baseline
|
It was developed using the classification method based on Vignos et al. to determine the functional status of the lower extremity.
It consists of 10 different levels, ranging from Level 1 (walks independently and climbs stairs) to Level 10 (bound to bed).
|
only baseline
|
|
Ambulation level- North star ambulatory assessment
Time Frame: only baseline
|
It consists of an item that allows the evaluation of activities that children frequently use in their daily lives, such as "standing up from a chair", "climbing steps", "stepping down", "standing up", "running".
Scoring; 2 = the activity is done unassisted, normally, 1 = the activity is done unassisted but in a modified form, and 0 = the activity cannot be done independently.
The total score ranges from 0-34.
A higher score indicates better ambulation and motor function.
It is a practical and valid reliable scale for children with DMD.
|
only baseline
|
|
Performance- 6 minutes walk test
Time Frame: only baseline
|
The 6-minutes walk test (6 MWT), which is valid and reliable for DMD patients, will evaluate the walking function and physical capacity of children at the submaximal level.
The distance the child walks for 6 minutes in a 25 m corridor will be recorded in meters.
A physiotherapist will walk with the children during the test and track the time with a stopwatch.
The 6 MWT is a simple test and considered an important outcome measure for children with DMD.
|
only baseline
|
|
Balance - Pediatric berg balance scale
Time Frame: only baseline
|
It is a test that functionally evaluates balance and consists of 14 parts, including parameters such as standing up from sitting, standing, transfers, taking steps, and turning.
Each section is scored between 0-4 and the highest score that can be obtained from the scale is 56.
High scores indicate good balance performance.
|
only baseline
|
|
Balance - Four square step test
Time Frame: only baseline
|
It is a valid and reliable test that has been used frequently in children in recent years to evaluate dynamic balance.
Sticks, each 90 cm long, are placed on the floor to form 4 squares and the squares are numbered from 1 to 4. For the test to be completed successfully, the child must quickly move from one square to the next without touching the sticks.
Performance is determined by measuring the test completion time in seconds.
Shorter completion time means better dynamic balance.
|
only baseline
|
|
Fear of falling - Pediatric Fear of Falling Questionnaire
Time Frame: only baseline
|
Its validity and reliability have been established in children with DMD.
The test consists of 34 items that question children's fear of falling during different activities in daily life.
It is scored as "0=Never", "1=Sometimes", "2=Always" and the highest possible score is 68.
Higher scores indicate greater fear of falling.
|
only baseline
|
|
Fall frequency
Time Frame: only baseline
|
How many times children have fallen in the last week (fall frequency) will be recorded.
|
only baseline
|
|
Gait - Gait Evaluation Scale in Duchenne Muscular Dystrpohy
Time Frame: only baseline
|
It consists of 10 items that examine the kinetic/kinematic condition of the foot, knee, hip, lumbar region, trunk, arm and head, support surface, walking speed and stride length, and each item is scored between 0 (worst) - 2 (best).
|
only baseline
|
|
Gait - Gait Classification Scale in Duchenne Muscular Dystrpohy
Time Frame: only baseline
|
It classifies gait with 5 levels, from Level 1 (Patient walks without compensation) to Level 5 (Patient cannot walk).
|
only baseline
|
|
Gait - Functional Evaluation Scale for Duchenne Muscular Dystrophy-Gait Domain
Time Frame: only baseline
|
It allows the compensatory movements of ambulatory children to be examined in detail through observation and provides a kinesiological analysis of gait by detecting and scoring compensatory movements.
The scale consists of 3 parts: stance phase, swing phase and general compensatory movements.
The points that can be obtained from the stance phase are between 0-23, the points that can be obtained from the swing phase are between 0-11, and the points that can be obtained from the general compensatory movements are between 0-13.
Lower scores indicate good performance.
|
only baseline
|
|
Cognitive level - Modified Mini Mental Test
Time Frame: only baseline
|
The Mini Mental Test developed for adults was adapted to the pediatric population by making minor modifications.
Test; It evaluates verbal responses including attention, orientation, memory and language skills, ability to obey verbal and written orders, write spontaneous sentences, and copy a complex drawing.
The highest score that can be obtained from this test is 37, the lowest score is 0. The total score reaches a plateau at approximately 9-10 years of age and corresponds to the scores of healthy adults.
Values below 27 points out of a total of 37 points in children over the age of 10 are indicative of mental retardation or dementia.
|
only baseline
|
|
Activity of daily living - The Functional Independence Measure for Children (WeeFIM)
Time Frame: only baseline
|
It consists of 6 sections and 18 items covering self-care, sphincter control, transfers, locomotion, communication, social and cognitive domains.
Each item is scored between 7 (completely independent) and 1 (fully assisted) and the total score is determined as a minimum of 18 (fully dependent) and a maximum of 126 (completely independent).
|
only baseline
|
|
Activity of daily living - ACTIVLIM
Time Frame: only baseline
|
It is a scale developed to evaluate activity limitations in all neuromuscular diseases, including adult and childhood, and has Turkish validity and reliability.
The scale includes 22 items that evaluate activities of daily living that require the use of the upper and lower extremities.
Scoring; "0 = cannot do the activity", "1 = has difficulty in doing the activity", "2 = can do the activity easily" and according to this score, the patients are asked to describe their level of difficulty in performing each activity.
The highest score that can be obtained from the test is 36, and higher scores indicate less activity limitations.
|
only baseline
|
|
Quality of life - The Pediatric Quality of Life Inventory (PedsQL)-Neuromuscular Module Turkish version PedsQL-3.0
Time Frame: only baseline
|
This scale, which was found to be valid and reliable to evaluate the quality of life of children with neuromuscular disease, consists of 3 parts containing a total of 25 items.
The first part contains 17 items about the disease, the second part contains 3 items about communication skills, and the third part contains 5 items about the family's financial resources and social support systems.
The scale consists of a child personal report and a parent report for children aged 5-18, while only a parent report for children aged 2-4.
Each item is scored between 4 (always a problem) - 0 (never a problem).
Scoring is converted to 0=100, 1=75, 2=50, 3=25, 4=0.
A higher score on the scale indicates a better health-related quality of life.
|
only baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Oznur YILMAZ, Prof, Hacetteoe University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 6, 2022
Primary Completion (Actual)
April 1, 2023
Study Completion (Actual)
May 1, 2023
Study Registration Dates
First Submitted
October 8, 2022
First Submitted That Met QC Criteria
October 8, 2022
First Posted (Actual)
October 12, 2022
Study Record Updates
Last Update Posted (Actual)
February 28, 2024
Last Update Submitted That Met QC Criteria
February 26, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022/13-45
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Dyne TherapeuticsRecruitingMuscular Dystrophies | Muscular Dystrophy, Duchenne | Duchenne Muscular Dystrophy (DMD) | Muscular Dystrophy, Duchenne and Becker Types | Genetic Disease, X-Linked | Genetic Disease, Inborn | DMD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Muscular Dystrophy (DMD) | Muscular Dystrophies... and other conditionsUnited States
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
PepGen IncWithdrawnDuchenne Muscular Dystrophy (DMD)United Kingdom
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
Clinical Trials on 10 meter walk test
-
University of AmericasEnrolling by invitationObesity | Frailty | Sarcopenia | Sarcopenic Obesity | Gait SpeedChile
-
Hacettepe UniversityCompletedParkinson Disease | Movement DisordersTurkey
-
Istanbul UniversityCompletedMorbid ObesityTurkey
-
Gazi UniversityCompletedMultiple SclerosisTurkey
-
Aline ReinmannCompleted
-
Kırıkkale UniversityRecruitingAutism Spectrum Disorder | Social Skills | Motor DisordersTurkey
-
Tezel Yıldırım ŞahanCompletedValidity and Reliability of The 3-Meter Backward Walk Test in Individuals With Lower Limb AmputationLower Limb Amputation Below Knee (Injury) | Lower Limb Amputation KneeTurkey
-
Mayo ClinicNova Southeastern UniversityCompletedHead and Neck CancerUnited States
-
University of CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
Khon Kaen UniversityCompleted